Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials

Hepatology Research

Volumn 44, Issue 3, 2014, Pages 259-269

  Sun, Ping ^a   Yang, Xiao ^a   He, Rui Qing ^a   Hu, Qing Gang ^a   Song, Zi Fang ^a   Xiong, Jun ^a   Zheng, Qi Chang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antiviral agent; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; INTERFERON; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILL; CONVULSION; DEPRESSION; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTHYROIDISM; KIDNEY ABSCESS; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; LOSS OF APPETITE; LYMPHOCYTOPENIA; MALAISE; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETINA HEMORRHAGE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

EID: 84895178531     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12115     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
3. Tsukuma H, Tanaka H, Ajiki W, Oshima A. Liver cancer and its prevention. Asian Pac J Cancer Prev 2005; 6: 244-250.
4. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
6. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235.
7. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
8. Nishiguchi S, Kuroki T, Nakatani S etal. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
9. Shamliyan TA, MacDonald R, Shaukat A etal. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009; 150: 111-124.
10. Ikeda K, Arase Y, Saitoh S etal. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus - Related liver cancer. Hepatology 2000; 32: 228-232.
11. Miyaguchi S, Watanabe T, Takahashi H, Nakamura M, Saito H, Ishii H. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology 2002; 49: 724-729.
12. Shiratori Y, Shiina S, Teratani T etal. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306.
13. Lin SM, Lin CJ, Hsu CW etal. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100: 376-382.
14. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 71-75.
15. Mazzaferro V, Romito R, Schiavo M etal. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554.
16. Sun HC, Tang ZY, Wang L etal. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465.
17. Lo CM, Liu CL, Chan SC etal. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842.
18. Chen LT, Chen MF, Li LA etal. Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255: 8-17.
19. Zhong JH, Li H, Li LQ etal. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol 2012; 38: 286-295.
20. Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer 2009; 124: 2982-2988.
21. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96: 975-981.
22. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010; 52: 889-894.
23. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287-292.
24. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 32: 851-858.
25. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011.
26. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
27. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269, W64.
28. Jin YJ, Shim JH, Lee HC etal. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26: 1380-1388.
29. Uenishi T, Nishiguchi S, Tamori A etal. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2006; 36: 195-200.
30. Cheng SQ, Wu MC, Chen H etal. [Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B]. Zhonghua Zhong Liu Za Zhi 2005; 27: 114-116.
31. Chen LT, Chen MF, Lee LA etal. Randomized phase III study of adjuvant interferon alfa-2b in hepatocellular carcinoma with curative resection. Hepatology 2005; 42 (Suppl 1): 237A-238.
32. Mazzaferro V, Romito R, Colombo M etal. Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report [EASL abstract]. J Hepatol 2004; 40: 34.
33. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89: 418-422.
34. Kubo S, Nishiguchi S, Hirohashi K etal. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-967.
35. Nishiguchi S, Kubo S, Tamori A etal. Randomized trial of postoperative long-term interferon-alpha on intrahepatic recurrence after resection of hepatocellular carcinoma related to hepatitis C virus: a preliminary report [abtract]. J Gastroenterol Hepatol 2000; 15 (Suppl): F9.
36. Nishiguchi S, Kubo S, Hirohashi K, Shuto T, Yamazaki O, Oka H. Effects of postoperative interferon-a on recurrence after curative resection in patients with hepatitis C virus-related hepatocellular carcinoma: a prospective randomized trial [abstract]. Hepatology 1999; 30: 212a.
37. Nishiguchi S, Kubo S. Randomized trial of post-operative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma and long-term outcome. In: Omata M, Okita K, eds. Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Tokyo: Springer Japan, 2004; 209-218.
38. von Marschall Z, Scholz A, Cramer T etal. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 437-448.
39. Dinney CP, Bielenberg DR, Perrotte P etal. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58: 808-814.
40. Wang L, Wu WZ, Sun HC etal. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003; 7: 587-594.
41. Imamura H, Matsuyama Y, Tanaka E etal. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207.
42. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507.
43. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
44. Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 2011; 305: 123-143.
45. Fujita N, Sugimoto R, Ma N etal. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat 2008; 15: 498-507.
46. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-945.
47. Foy E, Li K, Wang C etal. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148.
48. Liaw Y-F, Kao J-H, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-561.
49. Bian ZX, Shang HC. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2011; 154: 290-291; author reply 1-2.